THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL; ROYAL CANCER HOSPITAL;CANCER RESEARCH TECHNOLOGY LIMITED;THE INSTITUTE OF CANCER RESEARCH
发明人:
申请号：
IL20633010
公开号：
IL206330A
申请日:
2010.06.13
申请国别(地区):
IL
年份:
2015
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B&mdash；RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
